Benzinga's Top Pre-Market Gainers
Celgene (NASDAQ: CELGZ) moved up 100.84% to $6.25 in the pre-market session. Celgene's pancreatic cancer drug Abraxene improved overall survival rates in a phase III study.
Gilead Sciences (NASDAQ: GILD) soared 9.77% to $71.36 in the pre-market trading. Gilead Sciences announced positive results in mid-stage hepatitis C virus (HCV) infection study.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.